Quantcast

Latest Peyronie's disease Stories

2014-05-08 08:33:00

LYNBROOK, N.Y., May 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced its financial results for the first quarter ended March 31, 2014 and provided a corporate update. "Based on the positive results we reported this quarter in the human lipoma indication, we are enthusiastic about the upcoming initiation of an...

2014-05-07 08:31:39

CHESTERBROOK, Pa., May 7, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Bank of America Merrill Lynch Healthcare Conference to be held May 13-15, 2014 at the Wynn Hotel in Las Vegas. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at...

2014-05-05 08:27:27

1Q 2014 Net Revenues Increased 34% Over 1Q 2013 to $88.5 Million on Acquisition Growth and Launch Momentum for STENDRA and XIAFLEX in Peyronie's Disease CHESTERBROOK, Pa., May 5, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and, as...

2014-05-01 08:36:53

LYNBROOK, N.Y., May 1, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®)( )in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Thursday, May 8, 2014 to report its first quarter 2014 financial results and provide a corporate update....

2014-05-01 08:33:52

CHESTERBROOK, Pa., May 1, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Deutsche Bank Healthcare Conference to be held May 7-8, 2014 at the InterContinental Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 8:40 a.m....

2014-04-29 20:27:01

Company to Report Full 1Q 2014 Financial Results on Monday, May 5 CHESTERBROOK, Pa., April 29, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it is reducing its financial guidance for the full year 2014 due primarily to lower-than-expected revenues from Testim(®) testosterone gel. Auxilium's revised financial guidance is as follows ($ millions): Revised...

2014-04-28 08:31:12

Four Podium Sessions to Highlight New Analyses of Data from Pivotal Phase 3 Trials Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., April 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced presentations from multiple trials evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) in patients with Peyronie's disease (PD).These data will be presented at...

2014-04-14 12:32:51

Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These...

2014-04-08 04:22:15

2014: The Year of Innovation in Men's Health, According to New York Urology Specialists NEW YORK, April 8, 2014 /PRNewswire/ -- Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women. http://photos.prnewswire.com/prnvar/20140408/NY00250LOGO Over the past 25 years, care for diseases that affect women...

2014-04-07 08:29:11

STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related